TAK
$18.39
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
Intraday
Recent News
Alkermes CEO Pops Calls 2026 a “Really Exciting Year” as Orexin Agonists Near Narcolepsy Launch
Alkermes (NASDAQ:ALKS) CEO Richard Pops said the company is entering what he described as a “really exciting year” as the orexin agonist field moves closer to commercialization in narcolepsy, with broader ambitions in other disorders linked to wakefulness circuitry. Speaking in a conference panel di
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After Strong Multi‑Period Shareholder Returns
Recent returns and business profile Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after a period where its share price total return is 0.3% over the past 3 months and 15.4% year to date, set against mixed shorter term moves. Over the past month, the stock shows a 1.1% gain, with a flat 1 day move and a slight 0.2% decline over the past week, while the 1 year total return stands at 33.8% and the 3 year total return at 47.5%. The company reports revenue of ¥4.46b and net income of...
Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
DNLI stock jumps as investors eye an April 5, 2026, FDA decision on tividenofusp alfa for Hunter syndrome, a key catalyst for growth.